Cleveland BioLabs (CBLI) Slammed on Equity Placement News
Tweet
Share
E-mailGet Alerts CBLI Hot Sheet
Join SI Premium – FREE
Cleveland BioLabs, Inc. (Nasdaq: CBLI), is getting slammed following the announcement of a $23.5 million capital raise through a series of private placements, which will total about 8.81 million common shares.
The stock is down 12.4 percent ahead of the bell.
Click here for more color on the offering.
The stock is down 12.4 percent ahead of the bell.
Click here for more color on the offering.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
